Mirai Medical

Executive Summary

Mirai Medical is an Irish medical device and digital health company pioneering ePORE® therapy, a novel endoscopic ablation technology using pulsed electric fields (PEF) for gastrointestinal diseases, including cancers. Founded in 2019 and based in Galway, the company aims to provide endoscopists with a safe, fast, and effective platform that can be easily integrated into clinical workflows. ePORE® therapy has the potential to transform the treatment landscape by offering a non-surgical, minimally invasive option that could improve patient outcomes and reduce healthcare costs. With a focus on scalability, Mirai Medical is positioned to address a significant unmet need in gastroenterology, where endoscopic approaches are increasingly favored over traditional surgery. The company is still in the early stages of development, with no disclosed funding rounds or commercial products yet. However, its innovative PEF technology differentiates it from thermal ablation methods, potentially offering faster procedures with reduced side effects. Key upcoming milestones include initial clinical trials and regulatory clearances, which will be critical for proving safety and efficacy. If successful, Mirai Medical could capture a substantial share of the gastroenterology ablation market. The company's progress should be closely monitored as it moves toward first-in-human studies and seeks strategic partnerships or funding to advance commercialization.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial results for ePORE® therapy30% success
• Q4 2026FDA 510(k) clearance or IDE approval for gastrointestinal ablation25% success
• Q2 2026Strategic partnership or Series A funding round40% success